MD Anderson Cancer Center Madrid Biobank

The access to biological samples and associated clinical information has historically represented one of the principal barriers in Biomedical Research. During recent years, ethical criteria and regulation of these activities have been covered by the current Biomedical Research Law 14/2007 and RD1716/2011.
 
The objective of the Biobank is to promote translational research, contributing to an increase in scientific production and the quality of this. The Biobank is essentially a system with which to manage human biological samples destined to biomedical research,
organized as a technical unit with quality, order and destination criteria.
 
The unit is in charge of registering, processing, storing and managing the cession of samples, providing a sample and service catalog for researchers in the context of intramural and extramural projects:
  • Coordination of sample collection in multicenter studies.
  • Storage of existing collections under the protection of the Biomedical Research Law 14/2007 and Royal Decree 1716/2001 for Biobanks.
  • Control and administration of informed consent forms and/or clinical documents associated to samples deposited at the Biobank.
  • Preparation for conservation of samples of serum, plasma, blood and other types of biological material.Technical and scientific assessment in the creation of
    new collections and work methodology.
  • Reception and dispatch of samples and associated document management (Material Transfer Agreements).
  • Quality control in the treatment of DNA/RNA samples.
  • Histological techniques (preparation of paraffin blocks, frozen tissue,  ematoxylin-eosin or other types of staining/marking).
  • Cell techniques (Purification of peripheral blood mononuclear cells or PBLs, PBMCs), the cultivation of tumor cells, the maintenance of cell lines, etc.
  • Molecular techniques: extraction and quantification of frozen tissue DNA/RNA or tissue in paraffin, blood etc.
MD Anderson Madrid Biobank forms part of the National Biobank Network, promoted by the Carlos III Health Institute (ISCIII), currently coordinated by the National Center for Cancer Research (CNIO), in which 63 institutions participate (www.redbiobancos.es), in
addition to being integrated in the proposed European BiobankNetwork, BBMRI-ERIC).
 

COMPOSITION OF THE BIOBANK:

Data Controller : MD Anderson Cancer Center Foundation Spain.
Scientific Director: Dr. Juan F. García.
 
Consulting members:
  • Dr. Gemma Toledo
  • Dr. Jose Francisco Tomas
  • Dr. Raquel Oña
  • Dr. Raquel Bratos

Coordinator: Ana María Martín

SCIENTIFIC COMMITTEE

  • Dr. José F. Tomás, Hematology.
  • Dr. Luis Chiva, Gynecologic Surgical Oncology.
  • Dr. Antonio González, Medical Oncology.
  • Dr. Santiago González, Surgical Oncology.
  • Dr. Alejandro Rojo, Anatomic Pathology.

External members:

  • Dr. Manuel Morente (CNIO), Head of Tumor Bank, Molecular Pathology Program. National Cancer Research Center.
  • Dr. Santiago Montes Moreno, Anatomic Pathology Service, Coordinator of the Biobank solid sample Node HUMV/IFIMAV (Marques de Valdecilla G.H.).

ETHICS COMMITTEE

  • Dr. Luis Chiva, Gynecologic Surgical Oncology.
  • Dr. Antonio González, Medical Oncology.
  • Dr. Carlos Nuñez, Surgical Urology.
  • Dr. Santiago González, Surgical Oncology.
  • Dr. Natalia Carballo, Radiotherapy.

Applications:

Biobanks can cede their samples to any biomedical investigation meeting the requirements established by the law (Article 69, LIB; Article 34, Royal Decree 1716/2011); and on the condition that this possibility be included in the informed consent form signed by the sample donor.

If you are the principal investigator of a project and wish to apply for samples to carry out the project, please contact the MD Anderson Madrid Biobank:

Contact: